FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2733752510> ?p ?o ?g. }

• W2733752510 endingPage "274" @default.
• W2733752510 startingPage "268" @default.
• W2733752510 abstract "Background Anti-fibrotic drugs may interfere with wound-healing after major surgery, theoretically preventing sufficient bronchial anastomosis formation after lung transplantation (LTx). The aim of this study was to assess the impact of previous treatment with pirfenidone and nintedanib on outcomes after LTx in patients with idiopathic pulmonary fibrosis (IPF). Methods All patients with IPF undergoing LTx at the University of Munich between January 2012 and November 2016 were retrospectively screened for previous use of anti-fibrotics. Post-transplant outcome and survival of patients with and without anti-fibrotic treatment were analyzed. Results A total of 62 patients with IPF were transplanted (lung allocation score [mean ± SD] 53.1 ± 16.1). Of these, 23 (37.1%) received pirfenidone and 7 (11.3%) received nintedanib before LTx; the remaining 32 (51.6%) did not receive any anti-fibrotic drug (control group). Patients receiving anti-fibrotics were significantly older (p = 0.004) and their carbon monoxide diffusion capacity was significantly higher (p = 0.008) than in controls. Previous anti-fibrotic treatment did not increase blood product utilization, wound-healing or anastomotic complications after LTx. Post-transplant surgical revisions due to bleeding and/or impaired wound-healing were necessary in 18 (29.0%) patients (pirfenidone 30.4%, nintedanib 14.3%, control 31.3%; p = 0.66). Anastomosis insufficiency occurred in 2 (3.2%) patients, both in the control group. No patient died within the first 30 days post-LTx, and no significant differences regarding survival were seen during the follow-up (12-month survival: pirfenidone 77.0%, nintedanib 100%, control 90.6%; p = 0.29). Conclusion Our data show that previous use of anti-fibrotic therapy does not increase surgical complications or post-operative mortality after LTx. Anti-fibrotic drugs may interfere with wound-healing after major surgery, theoretically preventing sufficient bronchial anastomosis formation after lung transplantation (LTx). The aim of this study was to assess the impact of previous treatment with pirfenidone and nintedanib on outcomes after LTx in patients with idiopathic pulmonary fibrosis (IPF). All patients with IPF undergoing LTx at the University of Munich between January 2012 and November 2016 were retrospectively screened for previous use of anti-fibrotics. Post-transplant outcome and survival of patients with and without anti-fibrotic treatment were analyzed. A total of 62 patients with IPF were transplanted (lung allocation score [mean ± SD] 53.1 ± 16.1). Of these, 23 (37.1%) received pirfenidone and 7 (11.3%) received nintedanib before LTx; the remaining 32 (51.6%) did not receive any anti-fibrotic drug (control group). Patients receiving anti-fibrotics were significantly older (p = 0.004) and their carbon monoxide diffusion capacity was significantly higher (p = 0.008) than in controls. Previous anti-fibrotic treatment did not increase blood product utilization, wound-healing or anastomotic complications after LTx. Post-transplant surgical revisions due to bleeding and/or impaired wound-healing were necessary in 18 (29.0%) patients (pirfenidone 30.4%, nintedanib 14.3%, control 31.3%; p = 0.66). Anastomosis insufficiency occurred in 2 (3.2%) patients, both in the control group. No patient died within the first 30 days post-LTx, and no significant differences regarding survival were seen during the follow-up (12-month survival: pirfenidone 77.0%, nintedanib 100%, control 90.6%; p = 0.29). Our data show that previous use of anti-fibrotic therapy does not increase surgical complications or post-operative mortality after LTx." @default.
• W2733752510 created "2017-07-14" @default.
• W2733752510 creator A5004490260 @default.
• W2733752510 creator A5012574601 @default.
• W2733752510 creator A5016615120 @default.
• W2733752510 creator A5024274065 @default.
• W2733752510 creator A5024369406 @default.
• W2733752510 creator A5029748189 @default.
• W2733752510 creator A5030364116 @default.
• W2733752510 creator A5034207468 @default.
• W2733752510 creator A5035492584 @default.
• W2733752510 creator A5039750637 @default.
• W2733752510 creator A5043844807 @default.
• W2733752510 creator A5053291675 @default.
• W2733752510 creator A5053293174 @default.
• W2733752510 creator A5069448233 @default.
• W2733752510 creator A5077802539 @default.
• W2733752510 creator A5088641617 @default.
• W2733752510 date "2018-02-01" @default.
• W2733752510 modified "2023-10-13" @default.
• W2733752510 title "Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy" @default.
• W2733752510 cites W2000549992 @default.
• W2733752510 cites W2027497658 @default.
• W2733752510 cites W2028558343 @default.
• W2733752510 cites W2034383024 @default.
• W2733752510 cites W2039688361 @default.
• W2733752510 cites W2044788332 @default.
• W2733752510 cites W2057292199 @default.
• W2733752510 cites W2058234974 @default.
• W2733752510 cites W2060447671 @default.
• W2733752510 cites W2089756110 @default.
• W2733752510 cites W2120791222 @default.
• W2733752510 cites W2132227824 @default.
• W2733752510 cites W2138871107 @default.
• W2733752510 cites W2163885376 @default.
• W2733752510 cites W2167383172 @default.
• W2733752510 cites W2168666423 @default.
• W2733752510 cites W2263854054 @default.
• W2733752510 cites W2267777024 @default.
• W2733752510 cites W2280330931 @default.
• W2733752510 cites W2315538569 @default.
• W2733752510 cites W2550940244 @default.
• W2733752510 doi "https://doi.org/10.1016/j.healun.2017.07.002" @default.
• W2733752510 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28734935" @default.
• W2733752510 hasPublicationYear "2018" @default.
• W2733752510 type Work @default.
• W2733752510 sameAs 2733752510 @default.
• W2733752510 citedByCount "40" @default.
• W2733752510 countsByYear W27337525102018 @default.
• W2733752510 countsByYear W27337525102019 @default.
• W2733752510 countsByYear W27337525102020 @default.
• W2733752510 countsByYear W27337525102021 @default.
• W2733752510 countsByYear W27337525102022 @default.
• W2733752510 countsByYear W27337525102023 @default.
• W2733752510 crossrefType "journal-article" @default.
• W2733752510 hasAuthorship W2733752510A5004490260 @default.
• W2733752510 hasAuthorship W2733752510A5012574601 @default.
• W2733752510 hasAuthorship W2733752510A5016615120 @default.
• W2733752510 hasAuthorship W2733752510A5024274065 @default.
• W2733752510 hasAuthorship W2733752510A5024369406 @default.
• W2733752510 hasAuthorship W2733752510A5029748189 @default.
• W2733752510 hasAuthorship W2733752510A5030364116 @default.
• W2733752510 hasAuthorship W2733752510A5034207468 @default.
• W2733752510 hasAuthorship W2733752510A5035492584 @default.
• W2733752510 hasAuthorship W2733752510A5039750637 @default.
• W2733752510 hasAuthorship W2733752510A5043844807 @default.
• W2733752510 hasAuthorship W2733752510A5053291675 @default.
• W2733752510 hasAuthorship W2733752510A5053293174 @default.
• W2733752510 hasAuthorship W2733752510A5069448233 @default.
• W2733752510 hasAuthorship W2733752510A5077802539 @default.
• W2733752510 hasAuthorship W2733752510A5088641617 @default.
• W2733752510 hasConcept C126322002 @default.
• W2733752510 hasConcept C141071460 @default.
• W2733752510 hasConcept C2777714996 @default.
• W2733752510 hasConcept C2778341716 @default.
• W2733752510 hasConcept C2779832356 @default.
• W2733752510 hasConcept C2780171596 @default.
• W2733752510 hasConcept C2781244666 @default.
• W2733752510 hasConcept C2781448352 @default.
• W2733752510 hasConcept C2911091166 @default.
• W2733752510 hasConcept C71924100 @default.
• W2733752510 hasConcept C8443397 @default.
• W2733752510 hasConcept C90924648 @default.
• W2733752510 hasConceptScore W2733752510C126322002 @default.
• W2733752510 hasConceptScore W2733752510C141071460 @default.
• W2733752510 hasConceptScore W2733752510C2777714996 @default.
• W2733752510 hasConceptScore W2733752510C2778341716 @default.
• W2733752510 hasConceptScore W2733752510C2779832356 @default.
• W2733752510 hasConceptScore W2733752510C2780171596 @default.
• W2733752510 hasConceptScore W2733752510C2781244666 @default.
• W2733752510 hasConceptScore W2733752510C2781448352 @default.
• W2733752510 hasConceptScore W2733752510C2911091166 @default.
• W2733752510 hasConceptScore W2733752510C71924100 @default.
• W2733752510 hasConceptScore W2733752510C8443397 @default.
• W2733752510 hasConceptScore W2733752510C90924648 @default.
• W2733752510 hasIssue "2" @default.
• W2733752510 hasLocation W27337525101 @default.
• W2733752510 hasLocation W27337525102 @default.

• next